anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Stroke is the leading cause of long-term disability and ranks as the second most prevalent cause of mortality worldwide. According to data from the World Health Organization, since 2005, the global probability of a person experiencing a stroke has increased by 50 percent. It is expected that 1 in 4 individuals will face the risk of having a stroke in their lifetime. A stroke can result in significant loss of motor functions, communications abilities, weakness, or hemiparesis, leading to a diminished quality of life. Therefore, improving the rehabilitation process is evidently of paramount significance. Virtual reality has emerged as a novel strategy to improve neurological diseases; however, there is an absence of an immersive software designed specifically for stroke patients within a gamified environment. Therefore, the aim of RESET randomized controlled trial is to evaluate the effect of a gamified, fully immersive, and stroke-specific virtual reality software on disability in stroke patients.
OBJECTIVE: Glioblastoma with multiple foci (mGBM) and multiple brain metastases share several common features on magnetic resonance imaging (MRI). A reliable preoperative diagnosis would be of clinical relevance. The aim of this study was to explore the differences and similarities between mGBM and multiple brain metastases on MRI.
METHODS: We performed a retrospective analysis of 50 patients with mGBM and compared them with a cohort of 50 patients with multiple brain metastases (2-10 lesions) histologically confirmed and treated at our department between 2015 and 2020. The following imaging characteristics were analyzed: lesion location, distribution, morphology, (T2-/FLAIR-weighted) connections between the lesions, patterns of contrast agent uptake, apparent diffusion coefficient (ADC)-values within the lesion, the surrounding T2-hyperintensity, and edema distribution.
RESULTS: A total of 210 brain metastases and 181 mGBM lesions were analyzed. An infratentorial localization was found significantly more often in patients with multiple brain metastases compared to mGBM patients (28 vs. 1.5%, p < 0.001). A T2-connection between the lesions was detected in 63% of mGBM lesions compared to 1% of brain metastases. Cortical edema was only present in mGBM. Perifocal edema with larger areas of diffusion restriction was detected in 31% of mGBM patients, but not in patients with metastases.
CONCLUSION: We identified a set of imaging features which improve preoperative diagnosis. The presence of T2-weighted imaging hyperintensity connection between the lesions and cortical edema with varying ADC-values was typical for mGBM.
Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
BACKGROUND: Ruxolitinib (RUX), an orally administered selective Janus kinase 1/2 inhibitor, has received approval for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. We have previously demonstrated the anti-multiple myeloma effects of RUX alone and in combination with the immunomodulatory agent lenalidomide (LEN) and glucocorticosteroids both pre-clinically and clinically.
OBJECTIVE: This study aims to evaluate whether LEN can achieve clinical activity among patients with multiple myeloma progressing on the combination of RUX and methylprednisolone (MP).
METHODS: In this part of a phase I, multicenter, open-label study, we evaluated the safety and efficacy of RUX and MP for patients with multiple myeloma with progressive disease who had previously received a proteasome inhibitor, LEN, glucocorticosteroids, and at least three prior regimens; we also determined the safety and efficacy of adding LEN at the time of disease progression from the initial doublet treatment. Initially, all subjects received oral RUX 15 mg twice daily and oral MP 40 mg every other day. Those patients who developed progressive disease according to the International Myeloma Working Group criteria then received LEN 10 mg once daily on days 1-21 within a 28-day cycle in addition to RUX and MP, which were administered at the same doses these patients were receiving at the time progressive disease developed.
RESULTS: Twenty-nine subjects (median age 64 years; 18 [62%] male) were enrolled in this part of the study and initially received the two-drug combination of RUX and MP. The median number of prior therapies was six (range 3-12). The overall response rate from this two-drug combination was 31% and the clinical benefit rate was 34%. The best responses were 1 very good partial response, 8 partial responses, 1 minor response, 12 stable disease, and 7 progressive disease. The median progression-free survival was 3.5 months (range  0.5-36.2 months). The median time to response was 3.0 months. The median duration of response was 12.5 months (range 2.8-36.2 months). Twenty (69%) patients who showed progressive disease had LEN added to RUX and MP; all patients had prior exposure to LEN and all but one patient was refractory to their last LEN-containing regimen. After the addition of LEN, the overall response rate was 30% and the clinical benefit rate was 40%. The best responses of patients following the addition of LEN were 2 very good partial responses, 4 partial responses, 2 minor responses, 8 stable disease, and 4 progressive disease. The median time to response was 2.6 months (range 0.7-15.0 months). The median duration of response was not reached. The median progression-free survival following the addition of LEN was 3.5 months (range 0.3-25.9 months).
CONCLUSIONS: For patients with multiple myeloma, treatment with RUX and MP is effective and well tolerated, and LEN can be used to extend the benefit of this RUX-based treatment.
CLINICAL TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov, NCT03110822, and is ongoing.
NEW MATERIAL:A compound shown by formula I (R is lower alkyl; n is 1 or 2). EXAMPLE:cis-Oxalato[1-(2-aminopropyl)pyrrolidine]platinum(II). USE:An antitumor agent. PREPARATION:For example, a dihalogenoplatinum complex shown by formula II (X is Cl, Br or I) is reacted with silver nitrate to give a compound shown by formula III. Then this compound is reacted with disodium oxalate to give a compound shown by formula I. The compound shown by the formula II as a starting raw material is a novel substance and, for example, is produced by reacting a compound shown by the formula K2[Pt(II)X4] with a compound shown by formula IV in an aqueous solution at room temperature - 100 deg.C for 30min-12hr.
An oil in water emulsion adjuvant composition comprises a metabolizable oil, one or more surfactants, an antioxidant and a component to make the composition isotonic. The metabolizable oil can be squalene oil, soybean oil or sesame oil.  The antioxidant can be a-tocopherol or ascorbic acid.  The component to make the composition isotonic can be dextrose, glycerol, mannitol, sorbitol or polyethylene glycol.  The adjuvant composition can further contain a attenuated lipid A derivative. A vaccine containing an antigen and the adjuvant composition is useful for stimulating an immune response in a mammal.
PURPOSE: Dupilumab, an anti-interleukin-4 receptor alpha monoclonal antibody, is a new treatment for severe uncontrolled chronic rhinosinusitis with nasal polyps. However, data on the effect of dupilumab on histological changes in nasal polyp tissue are lacking. We aimed to investigate the effect of dupilumab on real-life clinical conditions and nasal polyp tissues from patients with eosinophilic chronic rhinosinusitis (ECRS), which is a refractory subtype.
METHODS: We conducted an open-label, prospective, observational, single-centre study on 63 patients with refractory ECRS on the basis of the criteria of the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study. These patients had a history of surgery and received dupilumab for 24 weeks. Patient-reported sinonasal symptoms, T&T olfactometry and nasal polyp scores were prospectively evaluated. In 23 patients with residual nasal polyps following dupilumab treatment, changes in systemic and local periostin expression, and total collagen deposition in nasal polyp tissues were investigated before and after dupilumab administration.
RESULTS: Dupilumab rapidly improved sinonasal symptoms and reduced the nasal polyp score 24 weeks after initiation. 40 (63.5%) patients had resolution of nasal polyps, but the reduction was limited in the remaining 23 (36.5%) patients. Periostin expression in serum and nasal lavage fluid was decreased, whereas periostin and the total collagen deposition area in subepithelial tissues in residual nasal polyps were enhanced after dupilumab administration.
CONCLUSION: Dupilumab improves sinonasal symptoms and reduces the nasal polyp score in refractory ECRS. Periostin-associated tissue fibrosis may be involved in the differential effect of dupilumab on nasal polyp reduction.
PURPOSE: Compounds useful for the treatment of conditions and diseases which are characterized by unwanted MP activity and potent inhibitors of metalloproteases are provided. CONSTITUTION: The compounds are those of Formula (I) or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof. Pharmaceutically-acceptable carriers or components thereof are sugars, tragacanth, malt, gelatin, talc and etc. In an embodiment of preparation of N-Hydroxy 1N-(4-Methoxyphenyl)sulfonyl-4N-methyl piperazine-2- Carbonari, paraformaldehyde (0.21 g, 6.84 mmol) is added to a solution of methyl ester of 1N-(4-methoxyphenyl)sulfonyl-piperazine-2-carboxyl acid hydrochloride(1.2 g, 3.4 mmol), sodium acetate (0.84 g, 10.26 mmol) in 10 mL of ethanol, followed by sodium cyanoborohydride (0.45 g, 6.84 mmol) slowly at room temperature. The reaction is stirred overnight at room temperature. The reaction mixture is concentrated under reduced pressure and stirred in 1 N HCI for 30 min. The mixture is made basic by 1 N NaOH, and extracted with EtOAc (3 x 80 mL) in the presence of some solid NaCl. The EtOAc layer is washed with brine, dried over MgS04, and concentrated under reduced pressure. The crude product is purified by column chromatography on silica gel using EtOAc.
Background: In the interventional study of gender mainstreaming, few studies have been conducted on gender empowerment in long-term care. And there are still some limitations in the gender curriculum of current in-service education. This research will cooperate with the digital learning promotion plan to stimulate learners' senses to strengthen their feelings about gender equality issues and events to have a more flexible and diverse learning experience and enhance geriatric care competencies.

Purpose: This study is a two-year plan, and the purpose of each year are as follows: 1). To conduct learning needs assessment of long-term care workers, and to develop and construct an educational training module for gender empowerment system of AR interactive experience.

2). To verify the effectiveness of the gender equality knowledge, attitude, awareness, and self-confidence of the research subjects after the "Apply of augmented reality technology" was introduced into the gender curriculum.

Methods: This study will adopt a mixed research approach. We'll conduct focus group interviews in the first year. The interviewers want to invite specialists in the fields of long-term care/geriatric nursing education, scholars from the gender talent pool of the Ministry of Education, and specialists in the engineering of digital smart systems. Additionally, it is intended to include senior front-line long-term care providers in the planning and creation of lesson plans for this platform system. A randomized clinical trial (RCT) will be adopted which uses a 2-armed, controlled experiment, parallel-group design, and multi-center in the second year. The setting and participants will be recruited from four long-term care institution in Taipei and New Taipei city. Through the cluster random sampling method, two institutions will be randomly selected from the computer based on the " institution " from each long-term care institution, and then the allocation concealment mechanism will be based on the inclusion criteria to recruit research participants, then according to their willingness to participate in this project. The intervention will be divided into two groups, namely treatment group (AR intervention group) and control group (waiting list control group). The experimental group's intervention consists of a course that embraces AR's platform for gender empowerment. The intervention course will require 50-60 minutes for preliminary planning, and participants in the experimental group can design at least three course modules to suit their learning needs. The control group will adopt the classroom narration method. The following are the primary outcome indicators: gender equality knowledge scale, gender equality attitude and awareness scale, self-confidence visual analog scale, learning effectiveness and System Usability Scale (SUS). The researcher uses structured questionnaires to collect data before intervention (To) and after intervention (T1), 1 month (T2) after the intervention. Data will be analyzed using the Generalized Estimating Equation to analyze the repeated measurements and intention-to-treat analysis for reducing attrition bias.
PURPOSE:To obtain a fungicide for Trichophyton useful for preventing and remedying athlete's food, by blending a viscous soft material with copper powder and an oil composition. CONSTITUTION:A soft material such as clay, etc., is blended with about 2.5-3wt.% copper powder and 1wt.% vegetable oil to give the aimed substance. Addition of perfume can extremely improve commercial value. When fingers or toes affected by Trichophyton are placed on the fungicide preparation for Trichophyton and strongly pressed to the preparation, the soft material containing copper powder is penetrated to the affected part at a narrow position between the fingers and Trichophyton at the part is destroyed with copper ion. The preparation can be simply deformed and stuck fast to Trichophyton occurring at the fingers and toes or other skin to treat the skin. The oil component blended with the soft material prevents corrosion, the preparation has high durability and no toxic verdigris resulting from corrosion is formed.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to cardiology, and deals with normalisation of functional reactivity of cardio-vascular system (CVS) in case of crisis course of arterial hypertension with disturbance of glucose tolerance. For this purpose estimation of CVS functional reactivity state under psychoemotional load is carried out by registration of systolic diastolic everage dynamic pressure (APav.dyn.) and heart rate (HR). On the basis of obtained data functional reactivity index (FRI) is determined before and after load, using the formula: FRI= APav.dyn.x HR)100 (conv. units). If FRI value after load increases on more than 20 conv.units, treatment including irbersartan 150 mg in the morning 1 time and lacidipine 4 mg in the morning 1 time during not less than 2 months. ^ EFFECT: such complex of medicamentary therapy in combination with empirically selected treatment duration ensures normalisation of CVS functional reactivity in said group of patients due to potentiation of therapeutic effect of applied medications. ^ 1 ex
The hyperpermeability of intestinal epithelium is a key contributor to the occurrence and development of systemic inflammation. Although D-beta-hydroxybutyrate (BHB) exhibits various protective effects, whether it affects the permeability of intestinal epithelium in systemic inflammation has not been clarified. In this study, we investigated the effects of BHB on the intestinal epithelial permeability, the epithelial marker E-cadherin and the tight junction protein Claudin-1 in colon in the lipopolysaccharide (LPS)-induced systemic inflammation mouse model. Intraperitoneal injection of LPS was used to induce systemic inflammation and BHB was given by oral administration. The permeability of intestinal epithelium, the morphological changes of colonic epithelium, the distribution and generation of colon E-cadherin, and the Claudin-1 generation and its epithelial distribution in colon were detected. The results confirmed the intestinal epithelial hyperpermeability and inflammatory changes in colonic epithelium, with disturbed E-cadherin distribution in LPS-treated mice. Besides, colon Claudin-1 generation was decreased and its epithelial distribution in colon was weakened in LPS-treated mice. However, BHB treatments alleviated the LPS-induced hyperpermeability of intestinal epithelium, attenuated the colonic epithelial morphological changes and promoted orderly distribution of E-cadherin in colon. Furthermore, BHB up-regulated colon Claudin-1 generation and promoted its colonic epithelial distribution and content in LPS-treated mice. In conclusion, BHB may alleviate the hyperpermeability of intestinal epithelium via up-regulation of Claudin-1 in colon in LPS-treated mice.
A frozen nutritional food product and method for oral delivery of nutrients, medicinal substances and other active ingredients via absorption through the oral mucosa for systemic effect. The frozen product includes at least one active ingredient, at least one flavoring agent, preservatives, food coloring, and a balance of water as a delivery liquid. The water is subjected to a magnetic treatment process and an ozonation process to enhance delivery of the active ingredients. More particularly, a first portion of the water is magnetized to neutralize the pH, increase oxygenation, and to improve the solubility of the ingredients mixed with the water. The remaining portion of the water is sterilized by ozonation, causing oxidation of undesirable metallic ions, odor and taste producing agents, and a wide variety of organics. Ozonation further increases the dissolved oxygen content of the water. The ingredients of the composition are thoroughly mixed and dissolved in the treated water to provide a solution which is frozen in the form of a Popsicle contained on a stick or within a plastic bag. When the frozen Popsicle comes into contact with the tissue of the oral cavity, the active ingredient(s) is absorbed through the mucosal and sub-lingual membranes and into the bloodstream.
Swedish data comes from a historical cohort of 424,386 clients of public dental clinics aged 23 and older in the Stockholm region with inception between October 2015 and January 2020, with follow-up from February 2020 to December 2020. In Sweden, the public dental clinics (Folktandvården, FTV) provide routine preventive visits (oral check-ups) to all residents who choose to receive care in these clinics. At each health check-up smoking and snus use are ascertained as past use, current use, and amount of current use. The national personal numbers assigned to every resident in Sweden at birth or at immigration will be used to obtain information on diagnoses of COVID-19 and of other diseases through record-linkage with regional health care registers. Demographic information will be extracted through record-linkage with the register of the total population of the Stockholm region held by Statistics Sweden.
Rising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide. Clinical trials, including ours, show relief of suicidal thoughts within hours of treatment with inexpensive, generic, subanesthetic ketamine. We have received NIMH R01 funding to conduct a clinical trial of intramuscular (IM) ketamine in unipolar or bipolar depressed adults who present to the CUIMC psychiatric ED with suicidality severe enough to require inpatient hospitalization as judged by ED clinical staff. Clinical staff will ask potentially eligible patients if they would like to learn more about the study, and if so, a research assistant (RA) will describe the study to the patient and perform a basic eligibility screen. Key exclusions are unstable medical problems, substance abuse, psychosis, and further detail is provided in the Inclusion/Exclusion criteria. Participants (N=90) who enroll will undergo baseline clinical ratings, brief cognitive testing, and then be randomized, double-blind, in a 2:1 ratio to a single IM injection of ketamine (n=60) or midazolam comparator (n=30). Vital signs and clinical state will be monitored until injection effects subside (approximately 2 hrs). Blood samples will be drawn at 60 minutes and 90 minutes postinjection to assay ketamine level and a genetic sample will be stored. All participants will then be admitted to the 9GN inpatient unit for standard clinical treatment with periodic research follow-up ratings through 4 weeks post-discharge from hospital. Ongoing outpatient treatment will be arranged by the inpatient clinical team. Positive results from this trial would support a novel, easy-to-use, inexpensive, and scalable intervention for busy emergency clinicians to implement.
Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session in the first week from a registered dietitian (RD), either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.
Individuals who volunteer to participate in the study will be evaluated considering the inclusion and exclusion criteria, and participants will participate in the study after reading and signing the Informed Consent Form. Tea workers who collect tea will be divided into 2 groups. .Demographic Information Form, Visual Analogue Scale (VAS), Upper Extremity Discomfort Analysis, Rapid Upper Extremity Assessment (RULA), Sleep Quality, Scandinavian Musculoskeletal System Questionnaire will be given to the participants of both groups. The surveys will be carried out face to face. After the application of the surveys, statistical data will be obtained. analyzes will be made. One group will be given exercise, the other group will not be given exercise. Post-exercise surveys will be conducted again to check the effectiveness of the exercise.
The present disclosure provides pharmaceutical formulations comprising d 4-domperidone of formula (I) or a pharmaceutically acceptable salt thereof. The formulation further comprises (i) glyceryl stearate and medium chain triglycerides; or (ii) polyoxylglycerides of stearic acid, a nonionic polyethylene oxide polymer, and a medium chain triglyceride; or (iii) a nonionic polyethylene oxide polymer and polyethylene glycol. The present disclosure also provides a method of treating a condition in a patient, the condition being gastroparesis, nausea unrelated to gastroparesis, emesis unrelated to gastroparesis, nausea related to gastroparesis, emesis related to gastroparesis, gastroesophageal reflux disease, hypogalactia, or a combination thereof, the method comprising administering to the patient a formulation described herein. In some aspects, the disorder is gastroparesis. In other aspects, the disorder is gastroesophageal reflux disease. In a further aspect, the disorder is hypogalactia.